Cancer
AstraZeneca’s cancer drug Tagrisso gets FDA approval
December 21, 2020Sales and Marketing AstraZeneca, Cancer, FDA
The FDA has approved AstraZeneca’s Tagrisso (osimertinib) for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated …
NICE shoots down Bristol-Myers Squibb immunotherapy Opdivo for post-surgery skin cancer
November 5, 2020Sales and Marketing BMS, Cancer, NHS, NICE, opdivo
NICE has rejected the routine use of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) on the NHS in England and Wales for …
University of Glasgow research details promising precision medicine approach in pancreatic cancer
October 12, 2020Research and Development, Sales and Marketing Cancer, Precision Medicine
Researchers at the University of Glasgow have unveiled a new precision medicine approach to identify and pair pancreatic cancer patients …
New Lenvima/Keytruda combo data in a range of cancers presented at ESMO 2020
September 21, 2020Research and Development, Sales and Marketing Cancer, ESMO2020, Eisai, Lenvima, MSD, keytruda
New data from two studies investigating the combination of Eisai’s multiple receptor tyrosine kinase inhibitor Lenvima (lenvatinib) and MSD’s blockbuster …
Piqray and Faslodex combo extends survival in HR+/HER2-, PIK3CA+ advanced breast cancer at ESMO 2020
September 21, 2020Research and Development, Sales and Marketing Cancer, ESMO 2020, Novartis, pharma
New data has been unveiled for the combination of Novartis’ Piqray (alpelisib) with AstraZeneca’s Faslodex (fulvestrant) in the treatment of …
Promising Phase 2 data for Sanofi and Regeneron’s PD-1 inhibitor Libtayo in locally advanced basal cell carcinoma
September 18, 2020Medical Communications, Research and Development Cancer, ESMO 2020, Libtayo, Regeneron, Sanofi, pharma
Promising Phase 2 data has been released at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 for Sanofi …
Oncology research in the age of COVID-19
September 14, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CAR T, CAR-T, Cancer, feature, pharma
Matt Fellows investigates the new challenges facing the oncology space and explores the strategies that can carry it through the disruptive …
Genetech scores sixth FDA approval in lung cancer with Gavreto
September 7, 2020Sales and Marketing Cancer, FDA, Genentech, lung cancer
Genentech’s once-daily oral therapy Gavreto (pralsetinib) has secured FDA backing in the treatment of metastatic rearranged during transfection (RET) fusion-positive …
University of Illinois at Chicago’s new breast cancer drug is safe and can halt disease progression, according to a Phase 1 trial
August 28, 2020Medical Communications Cancer, Cancers, breast cancer
A new breast cancer drug, called TTC-352, can halt the spread of the disease and is safe according to a …
Bristol Myers Squibb announces positive results from Opdivo clinical trials
August 12, 2020Research and Development Bristol-Myers Squibb, Cancer, bristol myers squibb
Bristol Myers Squibb has announced positive data from two Phase 3 clinical trials of its drug Opdivo. The first trial …
Novartis’ CAR T therapy Kymriah nails main goal in follicular lymphoma
August 4, 2020Manufacturing and Production, Research and Development CAR-T therapy, Cancer, Kymriah, Novartis, car t therapy
Novartis is celebrating the success of its one-time CAR T therapy Kymriah (tisagenlecleucel) in patients with relapsed or refractory (r/r) …
CAR T cell therapy is revolutionising cancer treatment, but at what cost?
August 3, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CAR T, CAR-T, Cancer, feature
CAR T cell therapy is one of the latest innovations in gene therapy. The process is primarily used to treat …
BioNTech’s melanoma vaccine shows promise in early interim analysis
July 30, 2020Research and Development BioNTech, Cancer, pharma
While the company has more recently drawn headlines for its COVID-19 efforts, BioNTech has unveiled promising interim Phase 1 data …
FDA committee backs GSK’s belantamab mafodotin in relapsed or refractory multiple myeloma
July 15, 2020Research and Development, Sales and Marketing Cancer, FDA, GSK, multiple myeloma, pharma
The FDA’s Oncologic Drugs Advisory Committee (ODAC) has moved to recommend the use of GlaxoSmithKline’s belantamab mafodotin, or GSK2857916 as …
Roche and Blueprint extend collaboration with $1.7 billion cancer drug development and commercialisation deal
July 14, 2020Manufacturing and Production, Research and Development Blueprint Medicines, Cancer, Roche, pralsetinib
Roche and Blueprint Medicines have come together in a $1.7 billion development and commercialisation partnership focused on precision therapy pralsetinib …
Latest content
Five Facts about cardiovascular disease
Artificial hearts: a century of innovation
